High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors

Lung Cancer（2023）

引用 0|浏览20

暂无评分

摘要

•Impact of bone tumor burden on survival upon bone targeted agents in aNSCLC pts treated with ICI is still unknown.•Our findings highlight a survival benefit in aNSCLC pts with HBTB treated with concomitant ICI and BTA, especially denosumab.•HBTB should be included as a stratification factor in future trials assessing BTA and ICI combinations inaNSCLC pts with BM.

查看译文

关键词

high bone tumor burden,immune checkpoint inhibitors,cell lung cancer,lung cancer,checkpoint inhibitors,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要